CD19 and B-cell chronic lymphocytic leukemia: Preclinical data indicate bispecific T-cell engager antibodies targeting CD3 and CD19 are efficacious against BTK/PLCG2 mutant CLL cells in vitro and in patient-derived xenograft models (127).